Photo from wikipedia
The Global Initiative for Chronic Obstructive Lung Disease noted a lack of convincing evidence for a survival benefit with inhaled therapy in COPD despite relevant improvements in lung function, exacerbations… Click to show full abstract
The Global Initiative for Chronic Obstructive Lung Disease noted a lack of convincing evidence for a survival benefit with inhaled therapy in COPD despite relevant improvements in lung function, exacerbations and patient reported outcomes. Interestingly, recent studies investigating the role of triple therapy with long-acting β2-agonist (LABA), long-acting muscarinic antagonist (LAMA) and inhaled glucocorticoid (ICS) showed that triple therapy could influence morbidity in patients with moderate to severe COPD. Plotting exacerbation rate versus mortality rate for the treatment groups in two recent controlled trials investigating triple therapy in COPD, there is a significant positive correlation supporting a positive impact of inhaled therapy on mortality https://bit.ly/35jbEiN
Journal Title: ERJ Open Research
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!